Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGG492 in Migraine Prevention
NCT01617941Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- May 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of selurampanel in migraine, sponsored by Novartis. Planned start May 2016; status: withdrawn.
02
Drugs
selurampanel
03
Conditions
migraine
Beyond the preview
Go deeper on NCT01617941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01617941.